Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis

T. Nukiwa, , A. Inoue, K. Kobayashi, M. Maemondo, S. Sugawara, S. Oizumi, H. Isobe, A. Gemma, Y. Saijo, H. Yoshizawa, S. Morita, K. Hagiwara, Final overall survival results of NEJ002, a phase III trial comparing gefitinib to carboplatin (CBDCA) plus paclitaxel (TXL) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations. Journal of Clinical Oncology. ,vol. 29, pp. 7519- 7519 ,(2011) , 10.1200/JCO.2011.29.15_SUPPL.7519

Jong-Mu Sun, Ki Hyeong Lee, Sang-we Kim, Dae Ho Lee, Young Joo Min, Hwan Jung Yun, Hoon Kyo Kim, Hong Suk Song, Yeul Hong Kim, Bong-Seog Kim, In Gyu Hwang, Keehyun Lee, Sook Jung Jo, Jae Won Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn, , Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial. Cancer. ,vol. 118, pp. 6234- 6242 ,(2012) , 10.1002/CNCR.27630

Mark G. Kris, Howard I. Scher, Vincent A. Miller, Maureen F. Zakowski, Francis M. Sirotnak, Efficacy of Cytotoxic Agents against Human Tumor Xenografts Is Markedly Enhanced By Coadministration of ZD1839 (Iressa), an Inhibitor of EGFR Tyrosine Kinase Clinical Cancer Research. ,vol. 6, pp. 4885- 4892 ,(2000)

Alice Tsang Shaw, D Ross Camidge, Jeffrey A. Engelman, Benjamin J. Solomon, Eunice Lee Kwak, Jeffrey W. Clark, Ravi Salgia, Geoffrey Shapiro, Yung-Jue Bang, Weiwei Tan, Lesley Tye, Keith D. Wilner, Patricia Stephenson, Marileila Varella-Garcia, Kristin Bergethon, A. John Iafrate, Sai-Hong Ignatius Ou, Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement. Journal of Clinical Oncology. ,vol. 30, pp. 7508- 7508 ,(2012) , 10.1200/JCO.2012.30.15_SUPPL.7508

W.K. (Bill) Evans, Gefitinib does not improve survival when combined with paclitaxel and carboplatin chemotherapy in people with advanced non-small-cell lung cancer Cancer Treatment Reviews. ,vol. 30, pp. 655- 659 ,(2004) , 10.1016/J.CTRV.2004.08.002

James Chih-Hsin Yang, Martin H. Schuler, Nobuyuki Yamamoto, Kenneth John O'Byrne, Vera Hirsh, Tony Mok, Sarayut Lucien Geater, Sergey V Orlov, Chun-Ming Tsai, Michael J. Boyer, Wu-Chou Su, Jaafar Bennouna, Terufumi Kato, Vera Gorbunova, Ki Hyeong Lee, Riyaz N.H. Shah, Dan Massey, Robert M. Lorence, Mehdi Shahidi, Lecia V. Sequist, LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. Journal of Clinical Oncology. ,vol. 30, pp. LBA7500- LBA7500 ,(2012) , 10.1200/JCO.2012.30.15_SUPPL.LBA7500

Ximing Tang, Hisayuki Shigematsu, B. Nebiyou Bekele, Jack A. Roth, John D. Minna, Waun Ki Hong, Adi F. Gazdar, Ignacio I. Wistuba, EGFR Tyrosine Kinase Domain Mutations Are Detected in Histologically Normal Respiratory Epithelium in Lung Cancer Patients Cancer Research. ,vol. 65, pp. 7568- 7572 ,(2005) , 10.1158/0008-5472.CAN-05-1705

Guanghui Gao, Shengxiang Ren, Aiwu Li, Jianfang Xu, Qinghua Xu, Chunxia Su, Jian Guo, Qinfang Deng, Caicun Zhou, Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials. International Journal of Cancer. ,vol. 131, ,(2012) , 10.1002/IJC.27396

Thomas R. Fleming, Standard versus adaptive monitoring procedures: a commentary Statistics in Medicine. ,vol. 25, pp. 3305- 3312 ,(2006) , 10.1002/SIM.2641

Luis Paz-Ares, None, Beyond first-line NSCLC therapy: chemotherapy or erlotinib? Lancet Oncology. ,vol. 13, pp. 225- 227 ,(2012) , 10.1016/S1470-2045(12)70001-3